Eiger doses first patient in Phase II Ultra trial of ubenimex to treat secondary lymphedema

US-based biopharmaceutical company Eiger has dosed the first patient in the Phase II Ultra trial of ubenimex to treat secondary lymphedema of the lower limbs.
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news